uniQure N.V. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your Rights - QURE

Core Viewpoint - uniQure N.V. is facing a class action lawsuit for alleged securities law violations, with shareholders encouraged to contact The Gross Law Firm regarding their rights [1] Allegations - The lawsuit claims that during the class period from September 24, 2025, to October 31, 2025, uniQure made materially false and misleading statements [1] - Allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA, and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline [1] - It is asserted that the statements made by the defendants regarding the company's business, operations, and prospects lacked a reasonable basis [1] Next Steps for Shareholders - Shareholders who purchased shares during the specified timeframe are urged to register for the class action by April 13, 2026, to potentially become lead plaintiffs [1] - Once registered, shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [1]